Table 2.
Reference | Age (y) | Sex | Presentation | Tocilizumab Dose (mg/kg/mo) | Treatment Duration (mo) | Concurrent Treatment | Response |
---|---|---|---|---|---|---|---|
Serelis et al (2015)53 | 32 | F | Nephrotic syndrome and 9.0 g/24 h proteinuria | 8 | 2 | Colchicine 1 mg, lisinopril 5 mg twice a day | Resolution of nephrotic syndrome, 3.0 g/24 h proteinuria |
Ugurlu et al (2017)54 | 36 | M | 12 g/24 h proteinuria | 8 | 6 | None | Resolved nephrotic syndrome, 2.1 g/24 h proteinuria |
44 | M | Baseline Cr 2.58 mg/dL, 23.7 g/24 h proteinuria | 8 | 5 | None | Cr 1.85 mg/dL and 14.9 g/24 h proteinuria | |
45 | M | Baseline Cr 1.28 mg/dL, 4.7 g/24 h proteinuria | 8 | 31 | None | Cr 1.12 mg/dL and 4.4 g/24 h proteinuria | |
47 | F | Baseline Cr 0.79 mg/dL, 2.1 g/24 h proteinuria | 8 | 31 | None | Cr 0.83 mg/dL and 1.4 g/24 h proteinuria | |
23 | M | Baseline Cr 0.69 mg/dL, 3 g/24 h proteinuria | 8 | 4 | None | Cr 0.71 mg/dL and 1.4 g/24 h proteinuria | |
35 | M | Baseline Cr 1.18 mg/dL, 1.7 g/24 h proteinuria | 8 | 28 | None | Cr 1.39 mg/dL and 2.7 g/24 h proteinuria | |
41 | F | Baseline Cr 0.71 mg/dL, 3 g/24 h proteinuria | 8 | 13 | None | Cr 0.64 mg/dL and 1.9 g/24 h proteinuria | |
39 | F | Baseline Cr 0.43 mg/dL, 1.6 g/24 h proteinuria | 8 | 32 | None | Cr 0.54 mg/dL and 0.7 g/24 h proteinuria | |
24 | F | Baseline Cr 0.4 mg/dL, 6 g/24 h proteinuria | 8 | 4 | None | Cr 0.35 mg/dL and 4.7 g/24 h proteinuria | |
22 | F | Baseline Cr 0.38 mg/dL, 1.8 g/24 h proteinuria | 8 | 20 | None | Cr 0.5 mg/dL and 0.1 g/24 h proteinuria | |
45 | F | Baseline Cr 0.79 mg/dL, 7.1 g/24 h proteinuria | 8 | 6 | None | Cr 0.93 mg/dL and 5.7 g/24 h proteinuria | |
21 | M | Baseline Cr 0.83 mg/dL, 11.7 g/24 h proteinuria | 8 | 4 | None | Cr 0.85 mg/dL and 16.7 g/24 h proteinuria |
Abbreviations: AA, serum amyloid protein; Cr, creatinine; eGFR, estimated glomerular filtration rate; F, female, M, male.